Host Tylah Tully sits down with Racura Oncology (ASX:RAC) executive director Peter Smith who talks through the company’s transformative quarter, marked by major intellectual property, clinical and funding milestones.

Smith explains the significance of securing composition of matter patent protection for (E.E)- Bisantrene, uncovering a novel anti-cancer mechanism of action and advancing multiple clinical programs including lung cancer, cardioprotection and AML.

The conversation also covers Rucura’s strengthened balance sheet and a busy year ahead with clinical readouts, trial expansions and regulatory progress firmly in focus.

Here is what he said: https://vimeo.com/1160936893?fl=pl&fe=sh